• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

    3/25/25 8:46:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MAIA alert in real time by email
    • Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)

     

    MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO).

    "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said Vlad Vitoc, M.D., CEO of MAIA. "Our poster features our latest findings on cytokine Interleukin-6 (IL-6) as a potential predictive immune response biomarker for THIO sequenced with a checkpoint inhibitor. Predictive biomarkers can further illuminate THIO's unique mechanisms of action which have shown exceptional efficacy in our Phase 2 clinical trial."

    Presentation details:

     

    Title:

    Phase 2 Study of Telomere-Targeting Agent THIO Sequenced by Cemiplimab in Immune Checkpoint Inhibitor-Resistant Advanced NSCLC: Interleukin-6 as a Potential Predictive Biomarker

    Abstract number:

    997

    Date:

    March 28, 2025

    Time:

    12:00 p.m. CET

    Presenter:

    Tomasz Jankowski, M.D., Ph.D. – Lead investigator for THIO-101 Phase 2 clinical trial

    Poster access:

    MAIA's poster will be available at maiabiotech.com/publications on March 28, 2025

    The European Lung Cancer Congress is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

    About Ateganosine

    Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

    About MAIA Biotechnology, Inc.

    MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

    Forward Looking Statements

    MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, "MAIA," "Company," "we," "our," and "us" refers to MAIA Biotechnology, Inc. and its subsidiaries.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250325817866/en/

    Investor Relations Contact

    +1 (872) 270-3518

    [email protected]

    Get the next $MAIA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MAIA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MAIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Guerrero Ramiro

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:17:45 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chaouki Steven M

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:50 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Louie Ngar Yee

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      7/2/25 4:16:10 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

      MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul, Turkey. The poster presentations highlight MAIA's lead telomere-targeting agent and next-generation treatments. The first presentation will be delivered by MAIA Scientific Advisory Board member, Z. Gunnur Dikmen, M.D., Ph.D., Hacettepe University, Faculty of Medicine, Department of Biochemistry in Ankara, Turkey. Poster

      7/1/25 9:00:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

      Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

      6/24/25 8:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

      Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA's telomere-targeting agent ateganosine (THIO), sequenced with Roche's checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers. "In preclinical studies, ateganosine was found to be highly synergistic and effective in combination w

      6/18/25 9:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Stan bought $50,000 worth of shares (33,333 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      6/5/25 4:42:27 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Guerrero Ramiro bought $30,000 worth of shares (20,000 units at $1.50), increasing direct ownership by 4% to 588,218 units (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:14:02 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smith Stan bought $99,999 worth of shares (66,666 units at $1.50) (SEC Form 4)

      4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

      5/12/25 4:12:43 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MAIA
    SEC Filings

    See more

    $MAIA
    Leadership Updates

    Live Leadership Updates

    See more

    $MAIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/25/25 9:55:20 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/24/25 9:15:10 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

      6/18/25 9:25:54 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

      Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

      6/24/25 8:15:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

      Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

      3/25/25 8:46:00 AM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

      Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos

      3/21/24 3:00:00 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

      SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 6:16:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MAIA Biotechnology Inc.

      SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 5:12:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by MAIA Biotechnology Inc.

      SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

      10/25/24 5:10:55 PM ET
      $MAIA
      Biotechnology: Pharmaceutical Preparations
      Health Care